Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 7Active not recruiting 6Withdrawn 4Recruiting 3Completed 3Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 8Genitourinary 4Thoracic 3Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 2Lymphoid 2Head & Neck 2Dermatologic 2Breast 2Other hematologic neoplasm 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Mesothelioma, Malignant 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 89Capecitabine 88Trastuzumab 81Docetaxel 81Paclitaxel 65Epirubicin 57pyrotinib 55Tamoxifen 54Letrozole 53Fulvestrant 49Vinorelbine 43Carboplatin 43Doxorubicin 41Radiotherapy 33Anastrozole 32exemestane 31Neoadjuvant Therapy 29palbociclib 27Drug Therapy 27Fluorouracil 24Bevacizumab 24pertuzumab 23Cisplatin 23eribulin 22Exercise 21130-nm albumin-bound paclitaxel 21Goserelin 20Gemcitabine 20Chemotherapy, Adjuvant 19Albumin-Bound Paclitaxel 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × avelumab × Breast × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT02630368 2022-02-02

METROmaJX

Institut Bergonié

Phase 1/2 Unknown
197 enrolled
BreastSarcoma

Breast Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡